Autopsy report · NCT02654639
Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
Cause of deathStaffing, sites or logistics
“Principal investigator left the institution”
Life of this trial
- Registered 1 month before it started.
- Ran for about 1 year 9 months before it stopped.
- 4 participants enrolled.
- Results were posted on the registry 9 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Georgetown University
- Sponsor type
- University, hospital or other
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- TAS-102; Bevacizumab
- Participants
- 4
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Detailed Clinical, Biochemical and Genetic Characterization in Gonadotropin-releasing Hormone (GnRH) Deficiency Disorders
“the Principal Investigator left the institution” - Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM
“Principal Investigator has left the institution” - Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
“Original Principal Investigator left the institution.” - Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.
“Principal Investigator left institution” - Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma
“The original principal Investigator left the institution.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.